Better binders. Fewer rounds. Six weeks to sequences.
Send us your antigen sequence. Designed candidates in 6 weeks, lab-validated binders in 9.
- VHH · Fab · scFv · IgG · minibinder
- You keep the IP
- No immunisation, no animal
Discover your perfect antibody
Assess your antibody characteristics
- CDR1
- CDR2
- CDR3
- N-glycosylation site
Improve the antibody you already have
- CDR1
- CDR2
- CDR3
- N-glycosylation site removed
Your project with us
Three ways to start with us
You have an antigen you need to target, with or without an epitope
Let's design your antibody by de novo protein design, from your antigen sequence, with anticipated developability.
You have a reference sequence of your antibody
We design your antibody around an existing sequence for higher diversity, developability, or for jumping to freedom to operate informed by prior art.
You already have antibody candidates
Tell us about your candidates and your objective. Sequences are shared later, under a confidentiality agreement. We check developability, specificity, and improve yield and thermostability before you commit to scale-up.
Kick-off + feasibility
Days (free)
Prototyping
2 weeks
Generative design & candidate selection
3-4 weeks
Wet-lab validation + QC
up to 3 weeks
Engagement is progressive. You never commit to the next step before the previous one has been a success either for the generation, redesign or developability check.
Supported capabilities
Antibodies
Candidate binders against the exact site you want, from your antigen sequence alone.
Miniprotein binders
Small, cheap-to-express binders for when an antibody scaffold is more than your target needs.
Antibody humanization
Cut immunogenicity risk without paying for it in affinity.
Developability optimization
Find the candidates that cannot survive development early, and re-engineer the ones that can.
Cross-reactivity
Bind the species your preclinical package needs. Miss the paralogue that would sink it.
Affinity maturation
Tighter binding designed on the interface itself, so you test tens of candidates instead of a library.
See it in action
Designed against the exact site you need
Six weeks to sequences against the site you named.
Our technology- AntigenYour target
- The epitope is specified, not random.
- Aggregation designed out
- Polyspecificity designed out
- Glycosylation designed out
We design the loops that grip your target. Developability profile
Computed before synthesis
- Sequence AInside the envelope on all five metrics
- Sequence BOutside on CDR loop lengthNot disqualified: one to look at harder
CDR loop lengthHydrophobic surfacePositive chargeNegative chargeVH–VL chargeTwo sequences from a natural repertoire, measured the same way as the 246 antibodies that reached the clinic. Shaded: the clinical envelope. Centre to edge: position among those 246. From your antigen to validated binders
Nine weeks to binders validated in the laboratory.
All servicesYour antigen
Sequence or structure
Your epitope
Specified, not random
De novo CDR design
Loops that grip your target
Developability filters
Computed before synthesis
- CDR loop length
- Hydrophobic surface
- Positive charge
- Negative charge
- VH–VL charge
Ranked candidates
Best ones to the wet lab
Illustrated with PDB 1MEL.
The data behind EVOBodies™
Our sources
- Clinical-stage antibodies
- Natural antibody repertoire
- Published developability metrics
- Published structure predictors
What it rests on
- 246antibodies that reached the clinic
- 500natural antibodies, naive B cells of one healthy donor
- 3independent structure predictors, so no single model decides
- 6Bparameters in ESMC, the language model behind ESMFold2
5 developability metrics, measured the same way on both sets
What you get
Ranked sequences with the epitope each engages, and a developability profile per candidate.
Each number in your report is attributable, so your team can check it.
Private by design
Your sequences and your target data serve your project, and nothing else.
Complete ownership
You keep all rights to the antibodies we design for you.
6 weeks
From your antigen to designed sequences.
9 weeks
To wet-lab validation of the candidates.
Start designing better antibodies
We design developable antibodies using AI in under 6 weeks, wet-lab validated in 9 weeks, from your antigen sequence. No immunisation, no phage display, no animal.
Clients and partners
Frequently asked questions
What is the expected timeline from our first conversation to delivery?
After our first discussion, we'll produce your free feasibility study in days, showing the confidence score for the next phases. Once you decide to move forward, you'll receive your designed antibody sequences after 6 weeks, wet-lab validated molecules from 9 weeks.
What starting material do I need to send you ?
Antigen sequence is enough.
How can I be confident this will work for my antigen ?
Every project starts with a free feasibility study, run before any commitment. We score your target from its 3D structure and tell you how much confidence we can have in generating antibodies against it. If that confidence is low, we say so plainly and we don't move forward, at no cost to you.
What is the background of IMMUNOCHEM?
Immunochem was founded in 1998 and spent its first two decades supplying high-quality research antibodies, with a speciality on small molecules. Since 2023, the company focuses on antibody discovery and generation by computational design, backed by wet-lab validation.
How to produce substantial amounts of antibodies in scale-up phase ?
Whatever the format (mAb, or single-domain antibody such as a nanobody or VHH), Immunochem delivers research-grade material and transfers the validated sequence and expression construct if appropriate. Gram-scale production runs with contract manufacturers.
Is the service available for my country?
The design work is computational and delivered digitally, so we serve customers worldwide from Belgium. Shipment of synthesised molecules follows standard research-reagent export rules, and no restriction applies in the European Union, the United Kingdom, Switzerland, the United States, India or China.